CY1121331T1 - Αγωγη αιματολογικων κακοηθειων me αντισωμα anti-cxcr4 - Google Patents
Αγωγη αιματολογικων κακοηθειων me αντισωμα anti-cxcr4Info
- Publication number
- CY1121331T1 CY1121331T1 CY20191100051T CY191100051T CY1121331T1 CY 1121331 T1 CY1121331 T1 CY 1121331T1 CY 20191100051 T CY20191100051 T CY 20191100051T CY 191100051 T CY191100051 T CY 191100051T CY 1121331 T1 CY1121331 T1 CY 1121331T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cxcr4
- disclosure
- maligrants
- hematological
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557815P | 2011-11-09 | 2011-11-09 | |
| US201161569113P | 2011-12-09 | 2011-12-09 | |
| PCT/US2012/064395 WO2013071068A2 (en) | 2011-11-09 | 2012-11-09 | Treatment of hematologic malignancies with an anti-cxcr4 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121331T1 true CY1121331T1 (el) | 2020-05-29 |
Family
ID=47179025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100051T CY1121331T1 (el) | 2011-11-09 | 2019-01-15 | Αγωγη αιματολογικων κακοηθειων me αντισωμα anti-cxcr4 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10428151B2 (enExample) |
| EP (1) | EP2776032B1 (enExample) |
| JP (1) | JP6541350B2 (enExample) |
| KR (1) | KR102024957B1 (enExample) |
| CN (1) | CN104039320B (enExample) |
| AU (1) | AU2012335553B2 (enExample) |
| BR (1) | BR112014011144A2 (enExample) |
| CA (1) | CA2855155A1 (enExample) |
| CY (1) | CY1121331T1 (enExample) |
| DK (1) | DK2776032T3 (enExample) |
| EA (1) | EA026153B1 (enExample) |
| ES (1) | ES2705001T3 (enExample) |
| HR (1) | HRP20182183T1 (enExample) |
| HU (1) | HUE043001T2 (enExample) |
| IL (1) | IL232517B (enExample) |
| LT (1) | LT2776032T (enExample) |
| MX (1) | MX357100B (enExample) |
| PL (1) | PL2776032T3 (enExample) |
| PT (1) | PT2776032T (enExample) |
| RS (1) | RS58102B1 (enExample) |
| SG (1) | SG11201401386XA (enExample) |
| SI (1) | SI2776032T1 (enExample) |
| SM (1) | SMT201900026T1 (enExample) |
| WO (1) | WO2013071068A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2625798T3 (es) * | 2006-10-02 | 2017-07-20 | E. R. Squibb & Sons, L.L.C. | Anticuerpos humanos que se unen a CXCR4 y usos de los mismos |
| ES2624981T3 (es) | 2011-07-01 | 2017-07-18 | Dana-Farber Cancer Institute, Inc. | Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario |
| EP3030322A2 (en) * | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| CA3206628A1 (en) * | 2013-09-12 | 2015-03-19 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
| JP6837837B2 (ja) * | 2013-11-06 | 2021-03-03 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｃｘｃｒ４抗体によるｃ１０１３ｇ／ｃｘｃｒ４関連ワルデンシュトレームマクログロブリン血症の治療 |
| US10612095B2 (en) | 2013-12-06 | 2020-04-07 | Dana-Farber Cancer Institute, Inc. | Methods to distinguish Waldenström's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance |
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| KR20240042192A (ko) | 2013-12-17 | 2024-04-01 | 크링 바이오테라퓨틱스 비.브이. | 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법 |
| US10066014B2 (en) * | 2014-02-06 | 2018-09-04 | Yeda Research And Development Co. Ltd. | Anti CD84 antibodies, compositions comprising same and uses thereof |
| KR20160132031A (ko) * | 2014-02-19 | 2016-11-16 | 마이크로콘스탄스 차이나 아이엔씨 | 케모카인 수용체 대항물질 및 그것의 병용 요법 |
| EP3242685B1 (en) * | 2015-01-09 | 2022-05-04 | AdAlta Limited | Cxcr4 binding molecules |
| MY188749A (en) | 2015-04-17 | 2021-12-28 | Bristol Myers Squibb Co | Compositions comprising a combination of nivolumab and ipilimumab |
| MX2017015811A (es) | 2015-06-12 | 2018-04-10 | Squibb Bristol Myers Co | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). |
| EP3744340A3 (en) | 2015-07-16 | 2021-03-03 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
| ES2907486T3 (es) * | 2015-09-24 | 2022-04-25 | Univ North Carolina Chapel Hill | Métodos y composiciones para reducir metástasis |
| EP3373929A4 (en) * | 2015-11-09 | 2019-07-03 | The General Hospital Corporation d/b/a Massachusetts General Hospital | UNIT DOSE FORMULATIONS FOR USE AS ANTI-FUGETACTIC AGENT |
| US10993985B2 (en) * | 2016-02-23 | 2021-05-04 | BioLmeRx Ltd. | Methods of treating acute myeloid leukemia |
| WO2017189999A1 (en) | 2016-04-29 | 2017-11-02 | Dana-Farber Cancer Institute, Inc. | Hck as a therapeutic target in myd88 mutated diseases |
| IL292302B2 (en) | 2016-05-20 | 2023-10-01 | Biohaven Pharm Holding Co Ltd | Use of glutamate modulating factors in cancer immunotherapy |
| CN109640979A (zh) * | 2016-06-16 | 2019-04-16 | 国家科学研究中心 | 用于减少干扰素水平的化合物 |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| WO2018143938A1 (en) * | 2017-01-31 | 2018-08-09 | Msm Protein Technologies Inc. | Anti-cxcr4 antibodies |
| KR102003179B1 (ko) * | 2017-02-21 | 2019-07-23 | 쿠라 온콜로지, 인크. | 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법 |
| WO2018183928A1 (en) | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
| WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | TUMOR TREATMENT METHODS |
| WO2019113456A1 (en) * | 2017-12-08 | 2019-06-13 | The Medical College Of Wisconsin, Inc. | Chemokine variants as immune stimulants |
| US20230181635A1 (en) | 2018-03-13 | 2023-06-15 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz | Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy |
| CA3093407A1 (en) | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| KR102825164B1 (ko) | 2018-03-27 | 2025-06-26 | 브리스톨-마이어스 스큅 컴퍼니 | 자외선 신호를 사용한 단백질 농도의 실시간 모니터링 |
| KR20200139724A (ko) | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| JP7645198B2 (ja) | 2019-05-23 | 2025-03-13 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞培養培地をモニターする方法 |
| KR20220098732A (ko) | 2019-10-08 | 2022-07-12 | 다나-파버 캔서 인스티튜트 인크. | 요법, 특히 myd88 돌연변이된 질환에 사용하기 위한 hck 억제제로서의 피라졸로피리미딘 유도체 |
| WO2022076318A1 (en) | 2020-10-05 | 2022-04-14 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| KR20240156411A (ko) | 2022-03-09 | 2024-10-29 | 브리스톨-마이어스 스큅 컴퍼니 | 치료 단백질의 일시적 발현 |
| CN120813375A (zh) * | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| CN119119196B (zh) * | 2024-08-01 | 2025-09-09 | 青岛大学 | 一种基于Motixafortide-喜树碱缀合物及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JP3367581B2 (ja) | 1993-10-14 | 2003-01-14 | 小野薬品工業株式会社 | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞 |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
| CA2536807C (en) | 2003-09-04 | 2010-07-13 | Medarex, Inc. | Expression vector |
| CA2597717C (en) | 2005-02-18 | 2014-10-21 | Dana-Farber Cancer Institute | Antibodies against cxcr4 and methods of use thereof |
| US8569280B2 (en) * | 2005-04-25 | 2013-10-29 | Immune Disease Institute | Methods for the treatment of multiple myeloma |
| US8258098B2 (en) | 2006-02-28 | 2012-09-04 | Pharma Mar, S.A. | Antitumoral treatments |
| ES2625798T3 (es) * | 2006-10-02 | 2017-07-20 | E. R. Squibb & Sons, L.L.C. | Anticuerpos humanos que se unen a CXCR4 y usos de los mismos |
| FR2915102B1 (fr) | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
| EA201071300A1 (ru) | 2008-05-14 | 2011-06-30 | Эли Лилли Энд Компани | Антитела к cxcr4 |
| WO2010043650A2 (en) | 2008-10-14 | 2010-04-22 | Ablynx Nv | Amino acid sequences directed against cellular receptors for viruses and bacteria |
| CN102369011A (zh) * | 2009-03-12 | 2012-03-07 | 健泰科生物技术公司 | 用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合 |
| DK2433124T3 (en) | 2009-05-19 | 2017-06-19 | Vivia Biotech Sl | PROCEDURES FOR PROVIDING PERSONALIZED MEDICAL EX VIVO TESTS FOR HEMATOLOGICAL NEOPLASMS |
| EP2605797A2 (en) | 2010-08-20 | 2013-06-26 | Cerulean Pharma Inc. | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
-
2012
- 2012-11-09 SI SI201231459T patent/SI2776032T1/sl unknown
- 2012-11-09 EP EP12787343.8A patent/EP2776032B1/en active Active
- 2012-11-09 US US14/356,996 patent/US10428151B2/en active Active
- 2012-11-09 CA CA2855155A patent/CA2855155A1/en not_active Abandoned
- 2012-11-09 HU HUE12787343A patent/HUE043001T2/hu unknown
- 2012-11-09 DK DK12787343.8T patent/DK2776032T3/en active
- 2012-11-09 RS RS20181552A patent/RS58102B1/sr unknown
- 2012-11-09 BR BR112014011144A patent/BR112014011144A2/pt not_active Application Discontinuation
- 2012-11-09 SM SM20190026T patent/SMT201900026T1/it unknown
- 2012-11-09 JP JP2014541315A patent/JP6541350B2/ja not_active Expired - Fee Related
- 2012-11-09 PT PT12787343T patent/PT2776032T/pt unknown
- 2012-11-09 WO PCT/US2012/064395 patent/WO2013071068A2/en not_active Ceased
- 2012-11-09 ES ES12787343T patent/ES2705001T3/es active Active
- 2012-11-09 EA EA201490957A patent/EA026153B1/ru not_active IP Right Cessation
- 2012-11-09 PL PL12787343T patent/PL2776032T3/pl unknown
- 2012-11-09 SG SG11201401386XA patent/SG11201401386XA/en unknown
- 2012-11-09 MX MX2014005267A patent/MX357100B/es active IP Right Grant
- 2012-11-09 AU AU2012335553A patent/AU2012335553B2/en not_active Ceased
- 2012-11-09 CN CN201280066551.7A patent/CN104039320B/zh not_active Expired - Fee Related
- 2012-11-09 HR HRP20182183TT patent/HRP20182183T1/hr unknown
- 2012-11-09 LT LTEP12787343.8T patent/LT2776032T/lt unknown
- 2012-11-09 KR KR1020147012396A patent/KR102024957B1/ko not_active Expired - Fee Related
-
2014
- 2014-05-08 IL IL232517A patent/IL232517B/en active IP Right Grant
-
2019
- 2019-01-15 CY CY20191100051T patent/CY1121331T1/el unknown
- 2019-10-01 US US16/590,152 patent/US20200231683A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX357100B (es) | Tratamiento de neoplasias hematologicas con un anticuerpo anti-cxcr4. | |
| JOP20200237A1 (ar) | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها | |
| CY1124723T1 (el) | Μορια προσδεσης pd-1 και μεθοδοι χρησης αυτων | |
| EA201891428A1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли | |
| EA201691858A1 (ru) | Композиции антител для лечения опухолей | |
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| CR20200467A (es) | Agentes anticuerpos anti-cd25 | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| PH12016500349B1 (en) | Anti-prlr antibodies and uses thereof | |
| CY1120359T1 (el) | Σταθερες φαρμακοτεχνικες μορφες αντισωματων εναντι ανθρωπινου υποδοχεα pd-1 προγραμματισμενου θανατου και σχετικες θεραπειες | |
| CY1117859T1 (el) | Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης | |
| EA201890158A1 (ru) | Антитела против ntb-a и связанные композиции и способы | |
| NZ737726A (en) | Multispecific antigen-binding molecules and uses thereof | |
| EA201590866A1 (ru) | Комбинация анти-cd20 антитела и селективного ингибитора киназы pi3 | |
| EA201490717A1 (ru) | АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ | |
| MX2020008768A (es) | Agentes anticuerpos anti-cd25. | |
| MX2022006891A (es) | Terapia combinada con liv1-adc y antagonista de pd-1. | |
| EA202090303A2 (ru) | Композиции антител для лечения опухолей | |
| TR201905240T4 (tr) | LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı. | |
| EA202092279A1 (ru) | Антитела к mica и/или micb и их применение | |
| EA202092151A1 (ru) | Антитела | |
| AR099798A1 (es) | Métodos y composiciones de anticuerpos para el tratamiento de tumores | |
| AR110165A1 (es) | Anticuerpos anti-met, moléculas biespecíficas de unión a antígeno que se unen a met, y métodos de uso | |
| EA201990258A1 (ru) | Антитела к tim-3 |